Notably, TRPV2 overexpression correlated with a poor prognosis in MM patients due to enhancement of the interaction between myeloma cells and bone marrow stromal cells by the channel's Ca2+ activity, causing osteoclast-mediated bone destruction. This evidence concerns the gene TRPV2 and Miyoshi myopathy.